EGFR and Opportunistic infection: These protocols could include pretreatment assessment of herpes virus immunity and coagulation status, with dynamic tracking of biomarkers like D-dimer for thrombosis and indicators of opportunistic infection (67, 68); Furthermore, EGFR-related oncological risks warrant enhanced malignancy screening in long-term users (68).